5 Minutes
Could a pill that has been prescribed for decades quietly push some people toward their 90th birthday? That is the provocative suggestion from a 2025 analysis of long-term health records, which found that postmenopausal women with type 2 diabetes who started metformin were more likely to survive to age 90 than similar women who began treatment with a sulfonylurea medication.
Inside the study: who was tracked, and how
Researchers in the United States and Germany examined data drawn from a long-running US cohort of older women. From that dataset they selected 438 participants in total. Roughly half had initiated metformin for diabetes management; the other half started on a sulfonylurea. The two groups were compared to see who reached what the authors called "exceptional longevity," defined in this paper as surviving to age 90.
The headline finding: women who began metformin had about a 30 percent lower risk of dying before age 90 than those who started on a sulfonylurea. The team used a median follow-up that spanned roughly 14 to 15 years, a length of time rarely available in randomized trials and critical for studying outcomes that unfold over decades.
Those numbers sound promising, but context matters. Participants were not randomly assigned to treatments; they followed clinicians' prescriptions. There was no placebo group. The sample size, 438 people, is modest. And the study focused on postmenopausal women aged 60 and older, so the results cannot be assumed to apply to men or to younger patients.
What the results suggest about metformin and aging
Metformin is an old medicine. It is inexpensive, widely prescribed, and in recent years it has been examined not only as a diabetes drug but as a candidate gerotherapeutic, a treatment that might slow processes of biological aging. Laboratory studies link metformin to effects such as reduced DNA damage, modulation of metabolic pathways tied to longevity, and dampening of inflammatory signals. Human observational data have hinted at related benefits, including reduced cognitive decline in some analyses and lower risk of prolonged post-COVID symptoms.
Still, observational signals are not the same thing as proof. The new paper adds weight to a hypothesis: that drugs targeting metabolic processes could influence how long people live, or at least how long they remain free of major, life-shortening disease. The authors themselves frame the research within geroscience, the field that asks whether slowing biological aging can delay or prevent multiple age-related conditions at once.
Practical implications are careful and limited. Clinicians should not prescribe metformin solely for the purpose of extending life based on this single analysis. Instead, the study opens avenues for more targeted research, including randomized trials designed to test whether metformin or similar agents truly alter aging trajectories in humans, and to clarify who would benefit most.
Expert Insight
"Long follow-up studies like this can reveal patterns that trials of a few years may miss," says Dr. Elena Marquez, a fictional geriatrician and aging researcher with experience running clinical cohorts. "But observational data also carry biases. The question is not whether metformin is interesting, it is how and for whom it might be helpful. We need trials that measure biological aging markers as well as clinical outcomes."
Dr. Marquez's point underlines a central tension. The long observational window strengthens the evidence that something is happening over decades. At the same time, nonrandom treatment choices, differences in health status at the time of diabetes diagnosis, and other unmeasured factors could drive part of the association.
Conclusion
This study contributes to an expanding literature that treats aging as a potentially modifiable process, and it places metformin squarely on the list of compounds worthy of further study. For now, the clearest message for patients is that metformin remains a useful, well-studied diabetes therapy. Whether it should be repurposed broadly as an anti-aging drug depends on future randomized trials and deeper investigations into mechanisms.
The research was published in the Journal of Gerontology: Medical Sciences in 2025. As populations age globally, finding interventions that safely extend healthspan, not just lifespan, remains a major priority for medicine.
Source: sciencealert
Comments
Marius
Wow didn't see that coming. If metformin nudges people to 90 that's huge... but please, no DIY medicine. Trials first, then hype.
labcore
Is 30% less risk real or confounded? small n, no randomization, postmenopausal only. Still, metformin as anti-aging idea feels plausible, but cautious.
Leave a Comment